| Product innovations | selenium in intensive care medicine |
| Keyhole Limpet Hemocyanin (KLH) | Integrated concept |
| Interferon therapy | D-Galactose |
Selenium in intensive care medicine |
||
|
Critical illness is frequently associated
with metabolic dysfunction or
tissue destruction. This leads to an
increased formation of free radicals,
which overwhelm the body’s antioxidative
protection system and are
difficult to eliminate. This leads to
deficiency in selenium. Early intervention
with sodium selenite pentahydrate,
the active substance in
selenase® , can compensate for this
deficiency. In addition to this, selenase® will support the body’s own
antioxidative protection system in the
degradation of the cell damaging
free radicals and thus enhance the
maintenance of the cellular immune
system.
Clinical studies have demonstrated the favorable effects of higher doses of sodium selenite. Early intervention with selenase® reduced lethality of patients with sepsis and acute pancreatitis. A prospective randomized clinical trial to improve these data is running. Patent information: „Kombinationspräparat zur Behandlung der Sepsis“
|